Immediate Impact

58 hit
Sub-graph 1 of 24

Citing Papers

CAR-T therapy in solid tumors
2025 Hit
Autophagy in tumor immune escape and immunotherapy
2025 Hit
2 intermediate papers

Works of Steven I. Blum being referenced

Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial
2022
CheckMate 459: Health-related quality of life (HRQoL) in a randomized, multicenter phase III study of nivolumab (NIVO) versus sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC).
2020

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Steven I. Blum 181 109 93 88 47 48 472
Chakkarin Burudpakdee 88 0.5× 36 0.3× 69 0.7× 54 0.6× 79 1.7× 42 478
Naomi Noguchi 77 0.4× 55 0.5× 56 0.6× 89 1.0× 39 0.8× 28 486
Elizabeth T Thomas 117 0.6× 127 1.2× 35 0.4× 31 0.4× 21 0.4× 32 457
K. Rettig 67 0.4× 82 0.8× 159 1.7× 63 0.7× 15 0.3× 38 527
Barbara Peil 83 0.5× 51 0.5× 43 0.5× 46 0.5× 18 0.4× 22 451
Gisèle Chvetzoff 78 0.4× 85 0.8× 192 2.1× 31 0.4× 22 0.5× 67 543
Mousumi Biswas 102 0.6× 30 0.3× 75 0.8× 33 0.4× 36 0.8× 33 416
Sheng‐Mao Chang 95 0.5× 60 0.6× 64 0.7× 14 0.2× 31 0.7× 33 446
Breanne Lechner 70 0.4× 43 0.4× 127 1.4× 75 0.9× 21 0.4× 19 408
Michele A. Faulkner 53 0.3× 44 0.4× 32 0.3× 43 0.5× 71 1.5× 41 524

All Works

Loading papers...

Rankless by CCL
2026